Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
SuperGen is developing its anticancer portfolio of six generic products and five enhanced or supergeneric products. The company currently anticipates marketing clearance of its first generic drug , mitomycin C , in late 1996. In April , 1996 the company announced the initiation of Phase I human trials with MitoExtra , its first supergeneric reformulation of an anticancer drug. SuperGen’s blood cell disorder products under development , all in Phase I/II human trials , target anemias associated with chemotherapy and radiotherapy , renal failure and aplastic anemia. The company’s obesity pill currently is in Phase II human clinical trials for general obesity and has been granted Orphan Drug Status for chronic genetic obesity. ( www.supergen.com )
SuperGen , Inc.
4140 Dublin Blvd. Suite 200
Dublin, California 94568
USA
Tel: (925) 560-0100
Fax: (925) 560-0101